Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high-risk clinical and ethnic groups with diabetes

被引：0
作者：
Allison B. Rosen
Andrew J. Karter
Jennifer Y. Liu
Joe V. Selby
Eric C. Schneider
机构：
[1] Beth Israel Deaconess Medical Center,Division of General Medicine and Primary Care
[2] Harvard School of Public Health,Department of Health Policy and Management
[3] Brigham and Women’s Hospital,Division of General Medicine
[4] Kaiser Permanente,Division of Research
[5] Northern California,undefined
来源：
Journal of General Internal Medicine | 2004年 / 19卷
关键词：
diabetes; renal disease; ACE inhibitors; angiotensin receptor blockers; secondary prevention;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
BACKGROUND: Diabetes causes 45% of incident end-stage renal disease (ESRD). Risk of progression is higher in those with clinical risk factors (albuminuria and hypertension), and in ethnic minorities (including blacks, Asians, and Latinos). Angiotensin-converting enzyme inhibitors (ACE) and angiotensin receptor blockers (ARB) slow the progression of diabetic nephropathy, yet little is known about their use among patients at high risk for progression to ESRD.
引用
收藏
页码：669 / 675
页数：6
相关论文
共 192 条
[1]  
Mokdad AH(2001)The continuing epidemics of obesity and diabetes in the United States JAMA 286 1195-200
[2]  
Bowman BA(2001)Prevention of end-stage renal disease due to type-2 diabetes N Engl J Med 345 910-2
[3]  
Ford ES(1995)Prognosis of diabetic patients on dialysis: analysis of Lombardy Registry data Nephrol Dial Transplant 10 1985-901
[4]  
Vinicor F(1989)Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes N Engl J Med 321 1074-9
[5]  
Marks JS(1992)The excess incidence of diabetic end-stage renal disease among blacks: a population-based study of potential explanatory factors JAMA 268 3079-84
[6]  
Koplan JP(1999)A community-based study of explanatory factors for the excess risk for early renal function decline in blacks vs whites with diabetes Arch Intern Med 159 1777-83
[7]  
Hostetter TH(1998)End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy Arch Intern Med 158 793-800
[8]  
Marcelli D(2002)Ethnic disparities in diabetic complications in an insured population JAMA 287 2519-27
[9]  
Spotti D(2001)Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 861-9
[10]  
Conte F(1993)The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1456-62
12345678910